Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-10-21
2011-12-13
Burkhart, Michael (Department: 1633)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S006110, C435S006140
Reexamination Certificate
active
08076077
ABSTRACT:
This invention provides a composition comprising the following polynucleotide probes: IL7R (AA485865) (SEQ ID NO:7), NDRGI (AA486403) (SEQ ID NO:8), EST1 (H50345) (SEQ ID NO:9), TRPC1 (AA017132) (SEQ ID NO:10), GFRA1 (AA512935) (SEQ ID NO:11), EST2 (AA454543) (SEQ ID NO:12), CLDN10 (R54559) (SEQ ID NO:13), DNALI1 (R93087) (SEQ ID NO:14), RBP5 (AA453198) (SEQ ID NO:15), EST3 (AA621761) (SEQ ID NO:16), EST4 (N63706) (SEQ ID NO:17), PCOLCE (AA670200) (SEQ ID NO:18), TDO2 (T72398) (SEQ ID NO:19), EST5 (T47454) (SEQ ID NO:20), HIST1H2BD (N33927) (SEQ ID NO:21), PXMP2 (N70714) (SEQ ID NO:22), ACAS2 (AA455146) (SEQ ID NO:23), ANAPC7 (T68445) (SEQ ID NO:24), EST6 (AA576580) (SEQ ID NO:25), RBP5 (N92148) (SEQ ID NO:26), ANXAI (H63077) (SEQ ID NO:27), CKB (AA894557) (SEQ ID NO:28), ITGBL1 (N52533) (SEQ ID NO:29), KPNA2 (AA676460) (SEQ ID NO:30), EST7 (W90740) (SEQ ID NO:31) and MEG3 (W85841) (SEQ ID NO:32). This invention further provides methods for determining the likelihood of recurrence of hepatocellular carcinoma (HCC) in a subject afflicted with HCC, for determining the likelihood of death of a subject afflicted with HCC or for determining whether to administer adjuvant therapy.
REFERENCES:
patent: 2003/0165854 (2003-09-01), Cunningham et al.
Beer, D.G. et al., “Gene-Expression Profiles Predict Survival of Patients with Lung Adenocarcinoma,” Nature Medicine, 2002, 816-824, vol. 8, No. 8.
Van'T Veer, L.J. et al., “Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer,” Nature, 2002, 530-536, vol. 415.
Kawai, H.F. et al., “α-Fetoprotein-Producing Hepatoma Cell Lines Share Common Expression Profiles of Genes . . . ,” Hepatology, 2001,676-691, vol. 33.
Sobin, L.H. and Wittekind, C., TNM Classification of Malignant Tumors, 1997, 5th ed., Wiley-Liss, New York, USA.
SAS Institute, SAS Macro Language: Reference, First Edition, 1997, 1st ed.
Fan, S-T. et al., “Hepatectomy for Hepatocellular Carcinoma: Toward Zero Hospital Deaths,” Annals of Surgery, 1999,322-330, vol. 229, No. 3.
Pisani, P. et al., “Estimates of the Worldwide Mortality from 25 Cancers in 1990,” Int. J. Cancer, 1999, 18-29, vol. 83.
El-Serag, H. B. and Mason, A.C., “Rising Incidence of Hepatocellular Carcinoma in the United States,” N. Engl. J. Med., 1999, 745-750, vol. 340.
Taylor-Robinson, S. et al., “Increase in Primary Liver Cancer in the UK, 1979-94,” The Lancet, 1997, 1142-1143, vol. 350.
Okuda, K. et al., “Changing Incidence of Hepatocellular Carcinoma in Japan,” Cancer Research, 1987, 4967-4972, vol. 47.
Tang, Z, “Hepatocellular Carcinoma,” Journal of Gastroenterology and Hepatology—Quadrennial Review, 2000, G1-G7, vol. 15.
Ng, I. et al., “Prognostic Significance of Pathologic Features of Hepatocellular Carcinoma . . . ,” Cancer, 1995, 2443-2448, vol. 76, No. 12.
Ng, I. et al., “Clinicopathologic and Prognostic Significance of the Histologic Activity of Noncancerous Liver Tissue in Hepatis B . . . ” Anatomic Pathology, 2002, 411-418.
Poon, R. et al., “Different Risk Factors and Prognosis for Early and Late Intrahepatic Recurrence . . . ,” Cancer, 2000, 500-507, vol. 89.
Poon, R. et al., “Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study . . . ” Annals of Surgery, 2001, 63-70, vol. 234, No. 1.
Poon, R. et al., “Clinicopathologic Features of Long-Term Survivors and Disease-Free Survivors . . . ,” J. Clin. Oncol., 2001, 3037-3044, vol. 19, No. 12.
Vauthey, J. et al., “Simplified Staging for Hepatocellular Carcinoma,” Journal of Clinical Oncology, 2002,1527-1536, vol. 20, No. 6.
Villa, E. et al., “Estrogen Receptor Classification for Hepatocellular Carcinoma: Comparison with Clinical Staging Systems,” J. Clin. Oncol., 2003, 441-446, vol. 21, No. 3.
Yeatman, T., “The Future of Cancer Management: Translating the Genome, Transcriptome, and Proteome,” Annals of Surgical Oncology, 2003, 7-14, vol. 10, No. 1.
Dhanasekaran, S. et al., “Delineation of Prognostic Biomarkers in Prostate Cancer,” Nature, 2001, 822-825, vol. 412.
Garber, M. et al., “Diversity of Gene Expression in Adenocarcinoma of the Lung,” PNAS, 2001,13784-13789, vol. 98, No. 24.
Pomeroy, S. et al., “Prediction of Central Nervous System Embryonal Tumour Outcome Based on Gene Expression,” Nature, 2002,436-442, vol. 415.
Singh, D. et al., “Gene Expression Correlates of Clinical Prostate Cancer Behavior,” Cancer Cell, 2002, 203-209, vol. 1.
Sorlie, T. et al., “Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications,” PNAS, 2001,10869-10874, vol. 98, No. 19.
Van De Vijver, M. et al., “A Gene-Expression Signature as a Predictor of Survival in Breast Cancer,” New Engl. J. Med., 2002, 1999-2009, vol. 347, No. 25.
Lee, J-S. and Thorgeirsson, S., “Functional and Genomic Implications of Global Gene Expression Profiles . . . ,” Hepatology, 2002, 1134-1143, vol. 35.
Okabe, H. et al., “Genome-wide Analysis of Gene Expression in Human Hepatocellular Carcinomas Using cDNA Microarray . . . ,” Cancer Research, 2001, 2129-2137, vol. 61.
Shirota, Y. et al., “Identification of Differentially Expressed Genes in Hepatocellular Carcinoma With cDNA Microarrays,” Hepatology, 2001,832-840, vol. 33.
Xu, X. et al., “Insight into Hepatocellular Carcinogenesis at Transcriptome Level by Comparing Gene Expression Profiles . . . ,” PNAS, 2001, 15089-15094, vol. 98, No. 26.
Chen, X., et al., “Gene Expression Patterns in Human Liver Cancers,” Molecular Biology of the Cell, 2002,1929-1939, vol. 13.
Cheung, S. et al., “Identify Metastasis-associated Genes in Hepatocellular Carcinoma through Clonality Delineation . . . ,” Cancer Research, 2002, 4711-4721, vol. 62.
Iizuka, N. et al., “Oligonucleotide Microarray for Prediction of Early Intrahepatic Recurrence of Hepatocellular Carcinoma . . . ,” The Lancet, 2003, 923-929, vol. 361.
Youden, W.J., “Index for Rating Diagnostic Tests,” Cancer, 1950,32-35.
Edmondson, H. and Steiner, P., “Primary Carcinoma of the Liver: A Study of 100 Cases among 48,900 Necropsies,” Cancer, 1954,462-503, vol. 7.
Gonzalez-Mariscal, L. et al., “Tight Junction Proteins,” Progress in Biophysics & Molecular Biology, 2003, 1-44, vol. 81.
Kastury, K. et al., “Complementary Deoxyribonucleic Acid Cloning and Characterization of . . . ,” Journal of Clinical Endrocrinology and Metabolism, 1997, 3047-3053, vol. 82, No. 9.
Schwartz, J. et al., “Neoadjuvant and Adjuvant Therapy for Resectable Hepatocellular Carcinoma: Review of the Randomised Clinical Trials,” The Lancet, 2002, 593-603, vol. 3.
Poon, R. et al., “Risk Factors, Prevention, and Management of Postoperative Recurrence After Resection of Hepatocellular Carcinoma,” Annals of Surgery, 2000, 10-24, vol. 232.
Muto, Y. et al., “Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients . . . ,” New Engl. J. Med., 1996, 1561-1567, vol. 334, No. 24.
Marill, J. et al., “Retinoic Acid Metabolism and Mechanism of Action: A Review,” Current Drug Metabolism, 2003, 1-10, vol. 4.
DeRisi, J. et al., “Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer,” Nature Genetics, 1996, 457-460, vol. 14.
Perou, C. et al., “Molecular Portraits of Human Breast Tumours,” Nature, 2000,747-752, vol. 406.
Sherlock, G. et al., “The Stanford Microarray Database,” Nucleic Acids Research, 2001, 152-155, vol. 29, No. 1.
Eisen, M. et al., “Cluster Analysis and Display of Genome-wide Expression Patterns,” Proc. Natl. Acad. Sci. USA, 1998, 14863-14868, vol. 95.
Bustin, S., “Absolute Quantification of mRNA Us
Cheung Siu Tim
Fan Sheung Tat
Burkhart Michael
Saliwanchik Lloyd & Eisenschenk
Versitech Limited
LandOfFree
Compositions and methods for prognosis and therapy of liver... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for prognosis and therapy of liver..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for prognosis and therapy of liver... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4315743